VHCP Management’s Larimar Therapeutics LRMR Stock Holding History

VHCP Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-50,176	Closed	-$1.99M	–	22
2016 Q3	$1.99M	Hold	50,176	–	–	1.96%	11
2016 Q2	$3.61M	Hold	50,176	–	–	3.74%	5
2016 Q1	$4.02M	Buy	50,176 +5,053	+11%	+$399K	3.49%	8
2015 Q4	$3.41M	Hold	45,123	–	–	2.06%	9
2015 Q3	$17.3M	Hold	45,123	–	–	4.44%	7
2015 Q2	$18.8M	Hold	45,123	–	–	5.29%	7
2015 Q1	$21.4M	Hold	45,123	–	–	4.94%	7
2014 Q4	$16.7M	Hold	45,123	–	–	4.59%	7
2014 Q3	$10M	Hold	45,123	–	–	4.5%	8
2014 Q2	$10.7M	Buy	+45,123	New	+$10.7M	5.72%	8

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VHCP Management's LRMR Position: Q4 2016 in Review

VHCP Management sold out of Larimar Therapeutics (LRMR) in Q4 2016, closing a stake of 50,176 shares — an estimated $1.99M sold.

VHCP Management first reported a position in LRMR in Q2 2014 and held it in 10 quarters. The position peaked at $21.4M in Q1 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

VHCP Management reported no remaining Larimar Therapeutics position as of Q4 2016 after selling out during the quarter.
VHCP Management sold 50,176 Larimar Therapeutics shares in Q4 2016, an estimated $1.99M.
VHCP Management first reported a position in Larimar Therapeutics in Q2 2014 and held it in 10 quarters.
VHCP Management's Larimar Therapeutics position peaked at $21.4M in Q1 2015.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.